Search
Vaccines Treatment Options
A collection of 947 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
169 - 180 of 947
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
Completed
This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
12/17/2024
Locations: Alliance for Multispecialty Research, LLC, Mobile, Alabama +19 locations
Conditions: Meningococcal Vaccine
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
Completed
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
Gender:
ALL
Ages:
All
Trial Updated:
12/17/2024
Locations: Aetion, Inc, New York, New York
Conditions: SARS-CoV-2
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Recruiting
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer. IO102-IO103 is a novel IDO and PD-L1 peptide based immune-modulatory therapeutic. It is designed to activate the patient's own immune cells (called T-cells) to fight the tumor and stop the tumor cells escaping from the body's immune system. IO102-IO103 works to directly kill tumor cells and remove the bod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Completed
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and ca... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
12/11/2024
Locations: North Alabama Research Center, Athens, Alabama +165 locations
Conditions: Influenza, COVID-19
Effects of Aging on Primary and Secondary Vaccine Responses
Completed
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the impaired vaccine responses in the elderly.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Stanford LPCH Vaccine Program, Stanford, California
Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Active Not Recruiting
This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
Completed
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 \[prototype Wuhan vaccine with Matrix-M adjuvant\] or NVX-CoV2601 \[Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant\]).
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
12/09/2024
Locations: ARS-Birmingham CRU, Birmingham, Alabama +49 locations
Conditions: COVID-19
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Completed
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up
Completed
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages affect the take-up of bivalent COVID-19 booster. The investigators will test the impact of sending text reminders as well as the importance of elevating vaccination intentions, facilitating action, and their combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: UCLA Health Department of Medicine, Quality Office, Los Angeles, California
Conditions: COVID-19, Vaccines
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
Completed
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5. The main focus is on safety: researchers want to see if this new booster is safe for teenagers who have already received two doses of the Pfizer or Moderna mRNA COVID-19 vaccines. To ensure a fair comparison, the study will use a double-blind approach. This means two groups of teenagers will receive booster shots,... Read More
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
12/04/2024
Locations: Alfa Medical Research, Davie, Florida +19 locations
Conditions: COVID-19
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
Completed
This is a phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 trimer Vaccine, Adjuvanted, in up to 48 healthy HIV-uninfected adult volunteers.
Gender:
ALL
Ages:
Between 18 years and 51 years
Trial Updated:
12/03/2024
Locations: George Washington University, Washington, District of Columbia +2 locations
Conditions: HIV Infections
CVD 37000: Immunity and Microbiome Studies At Intestinal and Systemic Sites in Ty21a Vaccinated Adults
Active Not Recruiting
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever affect the normal immune system and bacteria in the intestine. Patients having standard-of-care colonoscopies will be divided into 3 groups:
Group 1: Vivotif typhoid vaccination then colonoscopy; Group 2: Colonoscopy, then Vivotif typhoid vaccination, then follow-up colonoscopy; Group 3: Colonoscopy without vaccination.
The Vivotif typhoid vaccine used in this study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Universtiy of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland
Conditions: Typhoid Vaccination
169 - 180 of 947